Aadi Bioscience (NASDAQ:AADI) Stock, Quote.Headers.trade-ideas

Aadi Bioscience

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AADI

AIMD

AKRO

APVO

ASTR

BBAI

BCDA

BIVI

BTDR

BYND

CMCL

COIN

CRDF

CRML

DWAC

ETNB

FUFU

HSDT

IFBD

JAGX

JOAN

LIFW

MGEE

MINM

MSTR

NKTR

NYCB

OCEA

PHUN

PLTK

QNRX

RELI

RENB

RNLX

RVNC

SABR

SAVE

SBFM

SMCI

TRNR

VANI

ZJYL

Shares of  Bitdeer Technologies Group  (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin.

Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Pre-Market Outlook

ADIL

BBLG

Envoy Medical, Inc. - Class A Common Stock

COCH

DECK

QMCO

Shares of  BioVie Inc.  (NASDAQ: BIVI) fell sharply in today’s pre-market trading after the company reported pricing of public offering.

BioVie shares dipped 41.8% to $1.10 in pre-market trading

Here are some other stocks moving in pre-market trading.

Why BioVie Shares Are Trading Lower By Around 42%; Here Are 20 Stocks Moving Premarket

Long Ideas

DRRX

Kintara Therapeutics, Inc. - Common Stock

KTRA

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks That Are Preparing To Pump This Month

Aadi Bioscience Inc

Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript

TD Cowen analyst Tara Bancroft maintained a Buy rating on Aadi Bioscience (AADI – Research Report) today. The company's shares opened today at $1.9...

TD Cowen Keeps Their Buy Rating on Aadi Bioscience (AADI)

In a report released today, Robert Burns from H.C. Wainwright reiterated a Hold rating on Aadi Bioscience (AADI – Research Report). The company's s...

Aadi Bioscience (AADI) Receives a Hold from H.C. Wainwright

Notable earnings before Wednesday's open

Aadi Bioscience Q1 2024 Earnings Preview

Aadi Bioscience GAAP EPS of -$0.68 misses by $0.06, revenue of $5.4M misses by $1.29M

Aadi Bioscience, Inc. (AADI) Q1 2024 Earnings Call Transcript

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Aadi Bioscience</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/aadi-stock-quote/"><strong>AADI</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Aadi Bioscience reported earnings per share of -68 cents. This was below the analyst estimate for EPS of -64 cents.</li><li>The company reported revenue of $5.35 million.</li><li>This was 17.01% worse than the analyst estimate for revenue of $6.45 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/aadi-stock-earnings-aadi-bioscience-for-q1-of-2024/">AADI Stock Earnings: Aadi Bioscience Misses EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

AADI Stock Earnings: Aadi Bioscience Misses EPS, Misses Revenue for Q1 2024

H.C. Wainwright Sticks to Its Hold Rating for Aadi Bioscience (AADI)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>One of many stock market indexes used to measure performance, the <strong>Russell 2000</strong> is composed of 2,000 small-cap companies that make up the bottom two-thirds of the <strong>Russell 3000</strong> index. The reason is that the top 1,000 stocks in the Russell 3000 make up 93% of the index&rsquo;s market cap, so focusing on the lower 2,000 allows analysts and investors to judge the movement of the small-cap market more accurately.</p>



<p>It is an excellent way to gauge the performance of smaller economic sectors while also finding stocks to buy and sell. Moreover, the industry breakdown of the Russell 2000 has healthcare and technology at a combined 29% of the index, which means it is subject to the general volatility of those industries. That said, due to their small-cap nature, knowing which Russell 2000 stocks to sell is imperative to maximizing profits from a position before it fizzles out.</p>



<h2>AADI Bioscience (AADI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p>Tackling an incredibly complex and serious group of genetic disorders, <strong>AADI Biosciences </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/aadi-stock-quote/"><strong>AADI</strong></a></span>) has something of an uphill battle ahead of it. The company&rsquo;s drug pipeline focuses on treating cancers that occur due to malfunctions in what is called the <a href="https://www.cellsignal.com/pathways/mtor-signaling-pathway">mTOR signaling pathway.</a> That&rsquo;s significant because the mTOR pathway serves as a regulator in metabolic and physiological processes like building muscle or repairing damaged cells.</p>



<p>However, when overactive it can lead to cancer, diabetes and even depression &mdash; depending on additional factors. Thus, many of AADI&rsquo;s current drugs and drug pipelines focus on inhibiting this pathway to treat the aforementioned diseases. Unfortunately, despite one successful drug reaching the market and another <a href="https://www.aadibio.com/pipeline-clinical-studies/">entering regulatory trials</a> by year&rsquo;s end, the company has struggled to garner investor interest and has lost 31% of its value year-to-date.</p>



<p>As such, investors may want to sell now before another quarter of losses posted by its earnings report and wait to buy back in at a lower price depending on the progress of its next regulatory trials.</p>



<h2>Applied Optoelectronics (AAOI)</h2>



<div><img width="300" height="165" src="https://investorplace.com/wp-content/uploads/2017/03/aaoimsn-300x165.jpg" alt="cables"><div>Source: Shutterstock</div></div><p>With the gold rush of artificial intelligence data centers and computer processing networks, one would think that a company specializing in selling access networking technology would prosper. Yet, that hasn&rsquo;t been the story so far for <strong>Applied Optoelectronics </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/aaoi-stock-quote/"><strong>AAOI</strong></a></span>) in 2024. Despite the company&rsquo;s varied product applications for the telecom and data center industry, it has lost 56% of its value year-to-date.</p>



<p>Moreover, the company is now trading at a third of its 52-week price high and is still reeling from its disappointing <a href="https://investors.ao-inc.com/news-releases/news-release-details/applied-optoelectronics-reports-first-quarter-2024-results">first-quarter earnings report.</a> With revenue down by 23% year-over-year (YOY), the company&rsquo;s net losses amounted to $23 million in Q1 2024. While some of this can be chalked up to research and development, major increases in sales and marketing costs paired with a significant dip in its <a href="https://www.dictionary.com/browse/catv#:~:text=community%20antenna%20television%3A%20a%20cable,either%20poor%20or%20not%20possible.">community antenna television</a> sales hurt the company&rsquo;s long-term momentum.</p>



<p>Having only been in the Russell 2000 since June 11, 2024, the company has a ways to go but is still one of the index&rsquo;s worst performers for the year.</p>



<h2>Southern California Bancorp (BCAL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/07/californiastocks1600-300x169.jpg" alt="a picture of Los Angeles, California"><div>Source: Shutterstock</div></div><p>A regional banking company that has struggled to retain income over the years, <strong>Southern California Bancorp </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/bcal-stock-quote/"><strong>BCAL</strong></a></span>) has performed quite poorly year-to-date. For the <a href="https://stockanalysis.com/stocks/bcal/revenue/">first quarter of 2024,</a> the company&rsquo;s revenue sank 15.32% YOY. This put it at only $22.24 million for the quarter, lower than three out of the four prior quarters. </p>



<p>Even more concerning, the bank&rsquo;s net income dropped <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318302280&amp;type=HTML&amp;symbol=BCAL&amp;cdn=b443e9cded5d040aa9d4afe7533243ad&amp;companyName=Southern+Calif+Bancorp&amp;formType=10-Q&amp;formDescription=General+form+for+quarterly+reports+under+Section+13+or+15%28d%29&amp;dateFiled=2024-05-08">40% YOY,</a> bringing it to $4.94 million. When investing in <a href="https://investorplace.com/industries/financial/bank/">bank stocks,</a> the bank&rsquo;s cash flow and liquidity are key to its prospects of generating returns and further investor interest. Without these catalyzing factors, BCAL stock will likely continue to wither as it lacks the capital needed to make substantial investing decisions.</p>



<p>Thus, with this downtrend &mdash; likely due to the economic and quality of life struggles in Southern California &mdash; BCAL stock is among the most important Russell 2000 stocks to sell.</p>



<p><em>On the date of publication, Viktor Zarev&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines.</em></a></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>Viktor Zarev is a scientist, researcher, and writer specializing in explaining the complex world of technology stocks through dedication to accuracy and understanding.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/07/3-russell-2000-stocks-to-sell-in-july-before-they-crash-burn/">3 Russell 2000 Stocks to Sell in July Before They Crash &amp; Burn</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Russell 2000 Stocks to Sell in July Before They Crash & Burn

AAOI

ABEV

ACMR

ADRNY

AFRM

ALIT

ALSMY

ATHM

AVDL

BATRA

BCAL

BKSY

BMWYY

BWAY

BXSL

CLVT

CSTE

CWBHF

DINO

EDIT

ELAN

EURN

EVRI

FREY

FWONK

GENI

GILT

HAIN

HENKY

IFRX

IMUX

IMXI

INGR

INSW

INVZ

KLXE

KMDA

KPTI

KRNT

LBRDK

LCII

LSXMK

MCFT

MCRB

Opinion

Press Releases

Thinking about buying stock in Aadi Bioscience, Bitdeer Technologies, Aquestive Therapeutics, 89bio, or Energem?

Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update

Earnings

Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update

Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)

Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting

Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update

Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update

Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Aadi Bioscience

Aadi Bioscience (AADI) Forecast

Aadi Bioscience (NASDAQ:AADI) Stock, Quote.Headers.trade-ideas